TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023GlobeNewsWire • 08/23/23
TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment OptionGlobeNewsWire • 08/17/23
TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/15/23
TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023GlobeNewsWire • 08/09/23
TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary InfectionsGlobeNewsWire • 07/31/23
TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza VaccineGlobeNewsWire • 06/26/23
TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare ConferenceGlobeNewsWire • 05/23/23
TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/11/23
TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory DiseasesGlobeNewsWire • 05/04/23
TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB ProgramGlobeNewsWire • 05/01/23
TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial ResultsGlobeNewsWire • 03/07/23
TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive OfficerGlobeNewsWire • 02/08/23
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical OfficerGlobeNewsWire • 01/09/23